17 August 2017
Visiongain’s new report Global Anti-Inflammatory Therapeutics Market Forecast 2017-2027: Revenue Prospects by Indication (Arthritis, Respiratory, MS, Psoriasis, IBD, Other), Drug Class (Corticosteroids, Anti-Inflammatory Biologics, NSAIDs, Other) and Geography indicates that the Anti-Inflammatory Therapeutics market will see over $75bn in revenue in 2017.
The lead analyst of the report said:
“The Anti-Inflammatory Therapeutics market is expected to experience considerable growth over the forecast period. The main drivers for the growth include an increasingly ageing population, rising prevalence of arthritis and other immunological disorders and growing patient awareness of biologics and products available. In the US, more than 50 million adults and almost 300,000 children have arthritis or related conditions.
Between 2013-2015, around 54.4 million adults in the US (22.7% of all adults) had doctor-diagnosed arthritis, and 22.7 million (9.8%) had arthritis-attributable activity limitation. The prevalence of arthritis will increase in further years. The doctor diagnosed arthritis in US adults is forecast to 78.4 million (25.9% of all adults) in 2040 and the number of adults with arthritis-attributable activity limitation will increase to 34.6 million (11.4% of all adults). It was estimated that by 2040, one in four adults will have doctor-diagnosed arthritis. In UK, there are around 8 million adults have arthritis or related conditions.”
The 162-page report contains 108 tables, charts and graphs that add visual analysis in order to explain developing trends within the Anti-Inflammatory Therapeutics market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Anti-Inflammatory therapeutics submarkets, segmented by indication, including forecasts for Anti-Inflammatory Therapeutics for treating Arthritis, Respiratory conditions, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases and others. The Anti-Inflammatory Therapeutics market is also segmented by Drug Class, with forecasts for Corticosteroids, Anti-Inflammatory Biologics, NSAIDs and Other Anti-Inflammatory Therapeutics.
The 162-page report offers market forecasts and analysis for 11 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the Anti-Inflammatory Therapeutics field in detail.
The Global Anti-Inflammatory Therapeutics Market Forecast 2017-2027: Revenue Prospects by Indication (Arthritis, Respiratory, MS, Psoriasis, IBD, Other), Drug Class (Corticosteroids, Anti-Inflammatory Biologics, NSAIDs, Other) and Geography report will be of value to anyone who wants to better understand the Anti-Inflammatory Therapeutics market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the anti-inflammatory therapeutics industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.